Nabi Biopharmaceuticals Significantly Enhances NicVAX Patent Portfolio - MarketWatch

The United States Patent and Trademark duty issued U.S. Patent No. 7,776,620 entitled "Hapten-carrier conjugates for treating and preventing nicotine addiction" for the exclusive operate of methods for treating and preventing nicotine addiction with NicVAX and related nicotine vaccines. This patent runs down Dec 2018.

Nabi's patent portfolio for technology related to NicVAX encompasses a collection of issued and uncertain patents encircling the existence including five issued U.S. Claims in these patents are directed to essay of matter, or conjugate vaccines that comprise a nicotine-like whit linked to a carrier protein as bright-eyed as methods for the custom of these conjugate vaccines to treat and prevent nicotine addiction.

This patent complements our already issued composition-of-matter patents by providing for the exclusive appliance by Nabi and or its licensors a process to treat and prevent nicotine addiction using NicVAX as chipper as a broad departure of feasible nicotine vaccines," said Dr. Raafat Fahim, Head of the state and Manager Executive Officer of Nabi Biopharmaceuticals. The patent makes it extra tough for a rival to prosper a related vaccine.

Furthermore, as NicVAX is the isolated nicotine vaccine to get demonstrated statistically forceful proof-of-concept clinical results in a episode IIb smoking cessation study, Nabi's specific hapten and conjugate may prove to be an big component in developing an efficacious nicotine vaccine. Clearly, this patent as well solidifies Nabi's highbrow belongings estate for treating and preventing nicotine addiction with active immmunotherapeutics."

NicVAX is currently undergoing chapter III clinical testing to enable marketing authorization in the U.S. The firm initiated the front clinical analysis on Nov 3, 2009 and with enrolment complete, expects to chalk up ending info in the fourth quarter of 2011.

A moment Event III probation began in Parade 2010 and enrollment is hardy under course of action with final news expected in early 2012.

How NicVAX Works Nicotine is a inconsiderable iota that, upon inhalation into the lungs, quickly passes into the bloodstream and thereupon reaches the brain by crossing the blood-brain barrier.

Once in the brain, the nicotine binds to particular nicotine receptors, resulting in the proceeds of stimulants, such as dopamine, a chemical linked to enjoyment and to addiction. NicVAX stimulates the unaffected action to make antibodies that bind to nicotine, creating an antigen antibody manifold that is besides immense to cross the blood-brain barrier.

In this way, NicVAX blocks nicotine from reaching these receptors in the brain, fewer stimulants are released, and the pleasurable, highly-addictive belongings of nicotine are diminished, thereby manufacture it easier to forsake smoking.

Pre-clinical and preceding clinical material fireworks that NicVAX's energy to block nicotine from reaching the brain could ease citizens book smoking. Due to the nicotine antibodies circulate for far-off periods of time, Nabi believes NicVAX may besides be forceful in preventing smoking relapse and column long-term abstinence. This is a too earnest contrariness between NicVAX and existing anti-smoking treatment therapies.

Relapse is a denoting demanding facing smokers; with currently-available smoking cessation therapies, relapse rates can be as colossal as 90% in the inceptive year after a smoker quits.

Approximately Nabi Biopharmaceuticals Nabi Biopharmaceuticals leverages its exposure and doctrine in powering the unsusceptible manner to expand products that object grim medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse.

The gathering is headquartered in Rockville, Maryland. For more dirt about Nabi Biopharmaceuticals, please vacation www.nabi.com.

Forward-Looking Statements Statements in this release that are not strictly historical are forward-looking statements and consist of statements about products in development, results and analyzes of clinical trials and studies, evaluation and manner expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters.

You can make out these forward-looking statements by reason of they cover our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of budgeted events or circumstances. These forward-looking statements are not guarantees of coming performance and are man to risks and uncertainties that may beginning actual results to differ materially from those in the forward-looking statements as a crop of any unit of factors.

These factors include, on the contrary are not resident to, risks relating to our capability to frank and accomplish happy results from our two Sheet III clinical trials for NicVAX; GlaxoSmithKline Biologicals (GSK) failure to apply its choice for and successfully commercialize NicVAX; GSK's failure to successfully evolve and commercialize any prospect time candidate nicotine vaccine utilizing our mental property; our bent to commercialize NicVAX provided GSK does not manipulate its possibility for NicVAX; our influence to up thrust sufficient fresh money process to fully age and commercialize NicVAX whether GSK does not use the NicVAX option; our endowment to attract, retain and dispose explanation employees; our capacity to collect any too milestones and royalty payments under the PhosLo and PentaStaph agreements; the capacity to earn regulatory approval for NicVAX and any forthcoming day candidate nicotine vaccine in the U.S.